Turtle Cameron sold 2,638 shares of Spyre Therapeutics, Inc. at $91.49 for −$241k on Oct 1, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$241,350.62Shares × reported price
Shares traded
2,638Common Stock
Price per share
$91.49Reported price. Read footnotes for ranges.
% of reported position traded
0.48%This security and ownership context
Holdings after
546,619Direct
Trade date
Oct 1, 2026Sell
Filed
Oct 2, 2026, 9:29 PM ET2-day reporting delay
Accession
0001636282-26-000118Code S · Transaction 236171
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 549,257 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Oct 1, 2026Sell600$89.14−$53,484Trade 236169
Oct 1, 2026Sell2,683$90.10−$241,738.30Trade 236170
Oct 1, 2026Sell3,989$92.31−$368,224.59Trade 236172
Oct 1, 2026Sell4,990$93.37−$465,916.30Trade 236173
Oct 1, 2026Sell100$93.91−$9,391Trade 236174
6 transaction rows in this filing. Joint filers share the same rows.

SYRE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SYRE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −5%1w ago −6.5%1d ago −4.5%
Returns since7d −8%30d +3.6%90d180d1y

Footnotes in full

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3: Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.